TPRG1 Inhibitors
TPRG1 inhibitors encompass a variety of chemical compounds that diminish the functional activity of TPRG1 by targeting specific signaling pathways that TPRG1 is involved in. Compounds like Gefitinib and Erlotinib, which are EGFR inhibitors, decrease the signaling through the EGFR pathway, potentially leading to reduced TPRG1 activity by impacting the PI3K/AKT pathway that is crucial for cell survival and proliferation. Similarly, the PI3K inhibitors LY 294002 and Wortmannin, by inhibiting the PI3K/AKT pathway, decrease the activation of AKT, a kinase that could indirectly enhance TPRG1 function. Meanwhile, the mTOR inhibitor Rapamycin disrupts the mTORC1 complex, which is integral to protein synthesis and cell growth, processes where TPRG1 might be implicated, thus indirectly leading to a reduction in TPRG1 activity.
Further modulation of TPRG1 activity is achieved through the inhibition of the MAPK/ERK pathway by compounds suchas U0126 and PD 98059, MEK inhibitors that can indirectly result in diminished TPRG1 function due to the pathway's involvement in cellular processes that TPRG1 may influence. The RAF kinase inhibitor ZM 336372 and the multi-kinase inhibitor Sorafenib also contribute to this effect by inhibiting the RAF/MEK/ERK signaling cascade. Additionally, the JNK inhibitor SP600125 could reduce TPRG1 activity through its role in stress response pathways, while SB 203580's inhibition of p38 MAPK signaling could lead to decreased TPRG1 activity if TPRG1 is associated with inflammatory response signaling. Lastly, Sunitinib's broad inhibition of receptor tyrosine kinases like VEGFR and PDGFR may diminish TPRG1 activity by affecting the pathways that these receptors regulate, further demonstrating the diverse mechanisms by which these inhibitors can indirectly decrease the functional activity of TPRG1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor that can diminish the downstream signaling pathways such as the PI3K/AKT pathway, which when inhibited, can lead to a reduction in TPRG1 activity due to the role of AKT in promoting survival signals that may indirectly enhance TPRG1 function. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that disrupts the mTORC1 complex, leading to decreased protein synthesis and cell proliferation. Since TPRG1 is associated with cell growth, the inhibition of mTOR can indirectly decrease the functional activity of TPRG1. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib inhibits multiple receptor tyrosine kinases and can inhibit the RAF/MEK/ERK pathway, which might indirectly lead to diminished TPRG1 activity, as this pathway is involved in cell proliferation where TPRG1 may play a role. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY 294002 is a PI3K inhibitor that blocks the PI3K/AKT pathway, which is critical for cell survival and proliferation. The inhibition of this pathway could lead to decreased TPRG1 activity as it may rely on PI3K/AKT signaling for its function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK inhibitor that impedes the MAPK/ERK pathway, potentially leading to diminished TPRG1 activity since MAPK/ERK signaling is involved in various cellular processes including those in which TPRG1 may be implicated. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD 98059 is another MEK inhibitor that can decrease the activation of the ERK pathway, which could lead to decreased TPRG1 activity by indirectly affecting cellular processes that TPRG1 is involved in. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent PI3K inhibitor that can lead to reduced AKT phosphorylation and activity, potentially leading to decreased TPRG1 activity by affecting the same PI3K/AKT pathway that TPRG1 may utilize. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor, similar to Gefitinib, and can decrease EGFR signaling, leading to diminished TPRG1 activity by indirectly affecting downstream pathways such as PI3K/AKT that TPRG1 may be dependent on. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor that can reduce the activity of the JNK pathway, which is involved in stress response and apoptosis. Inhibition of JNK signaling could lead to diminished TPRG1 activity if TPRG1 is associated with this pathway. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB 203580 is a p38 MAPK inhibitor that can decrease the function of p38 MAPK, affecting inflammatory responses and potentially leading to diminished TPRG1 activity if TPRG1 is linked to p38 MAPK signaling. | ||||||